- By insider

President and CEO of Dicerna Pharmaceuticals Inc (30-Year Financial, Insider Trades) Douglas Fambrough (insider trades) bought 10,000 shares of DRNA on 09/01/2020 at an average price of $18.06 a share. The total cost of this purchase was $180,600.

• Warning! GuruFocus has detected 4 Warning Signs with DRNA. Click here to check it out.

• DRNA 15-Year Financial Data

• The intrinsic value of DRNA

• Peter Lynch Chart of DRNA

Dicerna Pharmaceuticals Inc is a biopharmaceutical company. It develops ribonucleic acid interference-based pharmaceuticals for treating diseases involving liver, including rare, chronic liver, cardiovascular and viral infections. Dicerna Pharmaceuticals Inc has a market cap of $1.33 billion; its shares were traded at around $17.84 with and P/S ratio of 14.47. Dicerna Pharmaceuticals Inc had annual average EBITDA growth of 12.40% over the past five years. GuruFocus has detected 3 severe warning signs with Dicerna Pharmaceuticals Inc. .

CEO Recent Trades:

• President and CEO Douglas Fambrough bought 10,000 shares of DRNA stock on 09/01/2020 at the average price of $18.06. The price of the stock has decreased by 1.22% since.

Directors and Officers Recent Trades:

• EVP & COO James B Weissman sold 4,360 shares of DRNA stock on 08/03/2020 at the average price of $22.47. The price of the stock has decreased by 20.61% since.

• See Remarks Bob D Brown sold 8,185 shares of DRNA stock on 08/03/2020 at the average price of $22.48. The price of the stock has decreased by 20.64% since.

For the complete insider trading history of DRNA, click here

.This article first appeared on GuruFocus.